Literature DB >> 12023995

Salmeterol for the prevention of high-altitude pulmonary edema.

Claudio Sartori1, Yves Allemann, Herve Duplain, Mattia Lepori, Marc Egli, Ernst Lipp, Damian Hutter, Pierre Turini, Olivier Hugli, Stephane Cook, Pascal Nicod, Urs Scherrer.   

Abstract

BACKGROUND: Pulmonary edema results from a persistent imbalance between forces that drive water into the air space and the physiologic mechanisms that remove it. Among the latter, the absorption of liquid driven by active alveolar transepithelial sodium transport has an important role; a defect of this mechanism may predispose patients to pulmonary edema. Beta-adrenergic agonists up-regulate the clearance of alveolar fluid and attenuate pulmonary edema in animal models.
METHODS: In a double-blind, randomized, placebo-controlled study, we assessed the effects of prophylactic inhalation of the beta-adrenergic agonist salmeterol on the incidence of pulmonary edema during exposure to high altitudes (4559 m, reached in less than 22 hours) in 37 subjects who were susceptible to high-altitude pulmonary edema. We also measured the nasal transepithelial potential difference, a marker of the transepithelial sodium and water transport in the distal airways, in 33 mountaineers who were prone to high-altitude pulmonary edema and 33 mountaineers who were resistant to this condition.
RESULTS: Prophylactic inhalation of salmeterol decreased the incidence of high-altitude pulmonary edema in susceptible subjects by more than 50 percent, from 74 percent with placebo to 33 percent (P=0.02). The nasal potential-difference value under low-altitude conditions was more than 30 percent lower in the subjects who were susceptible to high-altitude pulmonary edema than in those who were not susceptible (P<0.001).
CONCLUSIONS: Prophylactic inhalation of a beta-adrenergic agonist reduces the risk of high-altitude pulmonary edema. Sodium-dependent absorption of liquid from the airways may be defective in patients who are susceptible to high-altitude pulmonary edema. These findings support the concept that sodium-driven clearance of alveolar fluid may have a pathogenic role in pulmonary edema in humans and therefore represent an appropriate target for therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023995     DOI: 10.1056/NEJMoa013183

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  75 in total

Review 1.  Altitude illness.

Authors:  P W Barry; A J Pollard
Journal:  BMJ       Date:  2003-04-26

2.  At the heart of pulmonary oedema.

Authors:  Thierry Chinet
Journal:  J Physiol       Date:  2002-10-15       Impact factor: 5.182

3.  Prevention and Treatment of High-altitude Illness in Travelers.

Authors:  David R. Murdoch
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

4.  Hypoxia induced changes in lung fluid balance in humans is associated with beta-2 adrenergic receptor density on lymphocytes.

Authors:  Micah W Johnson; Bryan J Taylor; Minelle L Hulsebus; Bruce D Johnson; Eric M Snyder
Journal:  Respir Physiol Neurobiol       Date:  2012-07-03       Impact factor: 1.931

5.  The effect of 18 h of simulated high altitude on left ventricular function.

Authors:  Jesper Kjaergaard; Eric M Snyder; Christian Hassager; Thomas P Olson; Jae K Oh; Bruce D Johnson
Journal:  Eur J Appl Physiol       Date:  2006-09-21       Impact factor: 3.078

Review 6.  Nonventilatory treatments for acute lung injury and ARDS.

Authors:  Carolyn S Calfee; Michael A Matthay
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

7.  Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury.

Authors:  Markus Bosmann; Jamison J Grailer; Ketong Zhu; Michael A Matthay; J Vidya Sarma; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2012-02-07       Impact factor: 5.191

Review 8.  Alveolar epithelial beta2-adrenergic receptors.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-20       Impact factor: 6.914

Review 9.  Salmeterol (Serevent) asthma trial halted early.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

Review 10.  Role of endothelin-1 in acute lung injury.

Authors:  Alejandro P Comellas; Arturo Briva
Journal:  Transl Res       Date:  2009-03-20       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.